Potential Value of ctDNA NGS-based Analysis of Imatinib Resistant Secondary KIT Mutations to Select Second-Line Treatment for Patients with Advanced GIST
Findings from the exploratory analysis of the INTRIGUE study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
Adding Pembrolizumab to Chemotherapy with or without Bevacizumab Improves Overall Survival Across Subgroups of Patients with Persistent, Recurrent, or Metastatic Cervical Cancer
Findings from subgroup analyses of the KEYNOTE-826 study
FDA Approves Enfortumab Vedotin-ejfv with Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer
Evidence for efficacy is based on the results from the EV-302/KN-A39 study
Mosunetuzumab Plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed or Refractory Aggressive Large B Cell Lymphoma
Findings from the primary analysis of an ongoing phase Ib/II study
Oligoprogression in Metastatic NSCLC Could Be Effectively Treated with SBRT Plus Standard-of-Care, Leading to Increase in PFS Compared with Standard-of-Care Only
Findings from the CURB study
Divarasib in Combination with Cetuximab Demonstrates a Manageable Safety Profile and Promising Activity in Patients with KRAS G12C-positive CRC
Findings from patients with colorectal cancer included in arm C of a phase Ib study
Osimertinib Shows Promising Activity in Previously Untreated Patients with Metastatic NSCLC Harbouring Uncommon EGFR Mutations Other than the Exon 20 Insertion
Findings from the UNICORN study
Mirvetuximab Soravtansine-gynx Shows a Significant Benefit Over Chemotherapy in Women with Platinum-Resistant, FRα-positive Ovarian Cancer
Findings from the MIRASOL study
FDA Approves Enzalutamide for Non-Metastatic Castration-Sensitive Prostate Cancer with Biochemical Recurrence
Evidence for efficacy is based on the results from the EMBARK study
FDA Approves Pembrolizumab with Chemotherapy for HER2-negative Gastric or Gastro-Oesophageal Junction Adenocarcinoma
Evidence for efficacy is based on the results from the KEYNOTE-859 study
Talazoparib Plus Enzalutamide Improves rPFS in First-Line Treatment for Patients with mCRPC Harbouring HRR Gene Alterations
Findings from the TALAPRO-2 study
Adding Atezolizumab to First-Line Bevacizumab Plus Platinum Regimen Improves Survival in Patients with Metastatic, Persistent, or Recurrent Cervical Cancer
Findings from the ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030 study